1.2

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity…

4 days ago

Roquette Successfully Completes Inaugural EUR 1.2 billion Bond Offering to Support its Transformative Acquisition of IFF Pharma Solutions

Roquette Successfully Completes Inaugural EUR 1.2 billion Bond Offering to Support its Transformative Acquisition of IFF Pharma Solutions Lille, 26th…

2 weeks ago